Inactive Instrument

News VectivBio Holding AG

Equities

VECT

CH1109007893

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

VectivBio : Articles of Association of VectivBio Holding AG, as amended - Form 6-K	17/07/23	PU
VectivBio Holding AG(NasdaqGS:VECT) dropped from NASDAQ Composite Index	07/07/23	CI
ALENTIS THERAPEUTICS APPOINTS LUCA SANTARELLI AS CHAIRPERSON	30/06/23	AQ
Sector Update: Health Care Stocks Advancing Late Thursday	29/06/23	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	29/06/23	MT
Ironwood Pharmaceuticals, VectivBio Say Tender Offer for VectivBio Shares Completed	29/06/23	MT
Ironwood Pharmaceuticals, Inc. completed the acquisition of VectivBio Holding AG from Versant Venture Capital V, L.P., managed by Versant Venture Management, LLC, Forbion Growth Opportunities Fund II, managed by Forbion Capital Partners B.V., OrbiMed Advisors LLC and others.	28/06/23	CI
VectivBio Says Takeover by Ironwood Pharmaceuticals Approved at Extraordinary Shareholder Meeting	26/06/23	MT
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals	26/06/23	GL
Ironwood Pharmaceuticals Tender Offer for VectivBio Clears Antitrust Waiting Period	16/06/23	MT
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT	06/06/23	BU
VectivBio : Invitation to the Extraordinary General Meeting - Form 6-K	05/06/23	PU
VectivBio Holding Ag Approves Amendments to the Articles of Association	02/06/23	CI
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECT, RTL, APGN	01/06/23	PR
Moore Kuehn Encourages VECT, EMBK, BACK, and RADI Investors to Contact Law Firm	31/05/23	PR
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT	25/05/23	BU
Credit Suisse Downgrades VectivBio Holding to Neutral From Outperform on Heels of Announced Sale to Ironwood Pharmaceuticals, Lowers PT to $17 From $22	23/05/23	MT
Piper Sandler Downgrades VectivBio to Neutral From Overweight, Adjusts Price Target to $17 From $25	23/05/23	MT
SVB Securities Downgrades VectivBio to Market Perform From Outperform, Adjusts Price Target to $17 From $30	23/05/23	MT
VectivBio : IRONWOOD PHARMACEUTICALS, INC - Form 6-K	23/05/23	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News VectivBio Holding AG

Equities

VECT

CH1109007893

Summary

Filters